Abeona Therapeutics 관리

관리 기준 확인 2/4

Abeona Therapeutics CEO는 Vish Seshadri, Oct2021 에 임명되었습니다 의 임기는 3.08 년입니다. 총 연간 보상은 $ 2.85M, 19.5% 로 구성됩니다. 19.5% 급여 및 80.5% 보너스(회사 주식 및 옵션 포함). 는 $ 5.41M 가치에 해당하는 회사 주식의 2.07% 직접 소유합니다. 5.41M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 3.7 년입니다.

주요 정보

Vish Seshadri

최고 경영자

US$2.8m

총 보상

CEO 급여 비율	19.5%
CEO 임기	3.1yrs
CEO 소유권	2.1%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15

CEO 보상 분석

Vish Seshadri 의 보수는 Abeona Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$71m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$77m
Dec 31 2023	US$3m	US$555k	-US$54m
Sep 30 2023	n/a	n/a	-US$45m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$1m	US$505k	-US$43m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$84m
Mar 31 2022	n/a	n/a	-US$91m
Dec 31 2021	US$2m	US$255k	-US$85m

보상 대 시장: Vish 의 총 보상 ($USD 2.85M )은 US 시장( $USD 1.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Vish 의 보상이 증가했습니다.

CEO

Vish Seshadri (48 yo)

3.1yrs

테뉴어

US$2,847,442

보상

Dr. Vishwas Seshadri, also known as Vish, Ph.D. & M.B.A., serves as Chief Executive Officer, President and Director at Abeona Therapeutics Inc. since October 15, 2021. He served as the Senior Vice Presiden...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vishwas Seshadri	President	3.1yrs	US$2.85m	2.07% $ 5.4m
Joseph Vazzano	Chief Financial Officer	2.7yrs	US$1.49m	0.84% $ 2.2m
Brendan O'Malley	Senior VP & General Counsel	4.6yrs	US$1.17m	0.63% $ 1.6m
Brian Kevany	Senior VP	3.4yrs	데이터 없음	데이터 없음
Gregory Gin	Vice President of Investor Relations & Corporate Communications	no data	데이터 없음	데이터 없음
Alison Hardgrove	Chief People Officer	2.8yrs	데이터 없음	데이터 없음
Jon Voss	VP & Head of Quality	3.1yrs	데이터 없음	데이터 없음
Madhav Vasanthavada	Senior VP	1.2yrs	데이터 없음	데이터 없음
Carl Denny	Senior Vice President of Regulatory Affairs	no data	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

51.5yo

평균 연령

경험이 풍부한 관리: ABEO 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vishwas Seshadri	President	3.1yrs	US$2.85m	2.07% $ 5.4m
Mark Alvino	Independent Director	3.7yrs	US$336.14k	0.17% $ 432.6k
Faith Charles	Independent Director	3.7yrs	US$336.14k	0.26% $ 680.1k
Donald Wuchterl	Independent Director	3.6yrs	US$330.52k	0.26% $ 684.8k
Eric Crombez	Independent Director	less than a year	데이터 없음	0.025% $ 66.0k
Christine Berni-Silverstein	Independent Director	4.7yrs	US$324.89k	0.22% $ 582.9k
Leila Alland	Independent Director	3.6yrs	US$336.14k	0.27% $ 707.2k
Steven Gray	Member of Scientific Advisory Board	7.6yrs	데이터 없음	데이터 없음
Erika Augustine	Member of Scientific Advisory Board	7.6yrs	데이터 없음	데이터 없음
Jonathon Mink	Member of Scientific Advisory Board	7.6yrs	데이터 없음	데이터 없음
John Cooper	Member of Scientific Advisory Board	7.6yrs	데이터 없음	데이터 없음
Michael Amoroso	Chairman of the Board	3.7yrs	US$351.14k	0.33% $ 863.3k

3.7yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 이사회: ABEO 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Abeona Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Abeona Therapeutics Inc. Announces Board Appointments

Independent Director notifies of intention to sell stock

Independent Director recently bought US$52k worth of stock

Abeona Therapeutics Inc., Annual General Meeting, Apr 24, 2024

President recently bought US$88k worth of stock

Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer

Recent updates

Consensus EPS estimates fall by 14%

Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Consensus revenue estimates decrease by 33%, EPS upgraded

Abeona Therapeutics Inc. Announces Board Appointments

Independent Director notifies of intention to sell stock

Independent Director recently bought US$52k worth of stock

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$1.36 loss

Abeona Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $75.000174 million.

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Price target decreased by 7.1% to US$19.50

Consensus revenue estimates fall by 10%

New major risk - Financial position

Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel

Abeona Therapeutics Inc., Annual General Meeting, Apr 24, 2024

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

President recently bought US$88k worth of stock

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Forecast to breakeven in 2026

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

Forecast to breakeven in 2025

New minor risk - Share price stability

New minor risk - Insider selling

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. Appoints Madhav Vasanthavada as Chief Commercial Officer

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$2.08 loss in 2Q 2022)

Abeona Therapeutics Announces Additional Phase 3 Viital Study Results for Eb-101 Presented At the International Societies for Investigative Dermatology 2023 Meeting

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Price target increased to US$29.00

High number of new and inexperienced directors

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C and other investors

Consensus forecasts updated

Abeona Therapeutics Inc. announced that it expects to receive $35.000004 million in funding from Adage Capital Management, L.P., Armistice Capital LLC, EcoR1 Capital, LLC, Nantahala Capital Management, LLC, Deerfield Management Company, L.P. Series C

Abeona Therapeutics Inc. Announces Database Lock for Pivotal Phase 3 VIITAL Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Abeona Therapeutics Inc. Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Consensus forecasts updated

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Abeona Therapeutics Inc., Annual General Meeting, Aug 17, 2022

Consensus forecasts updated

Abeona crashes 21% as reverse stock split takes effect

Consensus revenue estimates increase by 95%

Nasdaq Grants Second 180-Day Period to Abeona Therapeutics to Regain Compliance with Minimum Bid Price Rule

Price target decreased to US$2.00

High number of new and inexperienced directors

Consensus forecasts updated

Abeona Therapeutics Inc. Reports Goodwill Impairment Charge for the Fourth Quarter Ended December 31, 2021

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Price target decreased to US$4.50

High number of new directors

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics Inc. Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 Viital Study for Recessive Dystrophic Epidermolysis Bullosa

Price target decreased to US$4.67

Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Value Index

Abeona Therapeutics shares rise after letter to stockholders

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

President notifies of intention to sell stock

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Independent Director recently sold US$310k worth of stock

Independent Director exercised options and sold US$342k worth of stock